Although immune cell PD-L1 expression and CD8+ infiltration are mentioned as markers correlated with (durable) response, none of the studies agree which predictive marker can be used in NSCLC patients.13–15 Therefore, the exact role of these specific immune cells in tumour inflammation and antitumour response to checkpoint inhibition therapy in NSCLC remains uncertain. The gene discussed is CD8A; the disease is neoplasm.